CytomX Therapeutics (CTMX) Financial Statements & Analysis

CytomX Therapeutics (CTMX) Income Statement

CytomX Therapeutics reported revenue of $76.20M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 44.8% from $138.10M a year earlier. CytomX Therapeutics posted a net loss of $17.37M, compared with net income of $31.87M a year earlier. Gross margin was 100.0% and operating margin -29.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $1.42M, down 92.4% from the same quarter a year earlier.

CytomX Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

CytomX Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	76.20	138.10	101.21	53.16	37.31	68.43	57.49	59.50	71.62
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	76.20	138.10	101.21	53.16	37.31	68.43	57.49	59.50	71.62
Operating Expenses
Research & Development	68.73	83.38	77.68	106.55	114.19	112.94	131.62	103.87	92.28
Selling, General & Administrative	29.84	29.73	30.02	40.45	39.16	36.03	36.77	33.51	25.61
Operating Expenses	98.57	113.11	107.70	154.50	153.35	148.97	168.38	137.38	117.88
Operating Income	-22.36	25.00	-6.48	-101.34	-116.04	-80.54	-110.90	-77.87	-46.26
Other Income/Expense
Interest Income	5.21	7.14	9.84	1.68	0.26	1.84	8.37	7.64	2.67
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.03	7.10	-0.03	2.02	0.17	29.63	8.23	7.57	2.65
Income
Income Before Tax	-17.13	32.09	3.32	-99.32	-115.87	-50.91	-102.67	-70.30	-43.61
Income Tax Expense	0.24	0.22	3.89	0.00	0.00	13.91	-0.43	14.30	-0.51
Net Income	-17.37	31.87	-0.57	-99.32	-115.87	-64.82	-102.24	-84.60	-43.10
Net Income - Continuous Operations	-17.37	31.87	-0.57	-99.32	-115.87	-64.82	-102.24	-84.60	-43.10
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-20.99	26.76	-4.31	-91.39	-113.16	-77.97	-100.06	-75.99	-41.97
EBIT	-22.36	25.00	-6.48	-93.84	-116.04	-80.54	-	-	-
Depreciation & Amortization	1.38	1.77	2.18	2.44	2.71	2.57	2.61	1.88	1.65
Earnings Per Share
Basic EPS	-	-	-	-2.00	-1.00	-1.00	-2.00	-2.00	-1.00
Diluted EPS	-	-	-	-2.00	-1.00	-1.00	-2.00	-2.00	-1.00
Basic Shares Outstanding	137.94	84.44	73.81	65.74	64.15	46.15	45.34	41.66	37.17
Diluted Shares Outstanding	137.94	84.75	73.81	65.74	64.15	46.15	45.34	41.66	37.17

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About CytomX Therapeutics Financial Statements

What was CytomX Therapeutics's revenue in fiscal 2025?

CytomX Therapeutics reported revenue of $76.20M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 44.8% from $138.10M a year earlier.

Is CytomX Therapeutics profitable?

No. CytomX Therapeutics reported a net loss of $17.37M in fiscal 2025. In fiscal 2024 it earned $31.87M.

What is CytomX Therapeutics's operating margin?

CytomX Therapeutics's operating income was −$22.36M on revenue of $76.20M in fiscal 2025, an operating margin of -29.3%, compared with 18.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition